[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370726-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370726-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-the-oncoprotein-rlip-as-novel-therapy-for-ovarian-cancer-research-highlights","Targeting the oncoprotein RLIP as novel therapy for ovarian cancer - Research highlights","","Ral-interacting/binding protein (RLIP/RalBP1) is a multifunctional protein linked to solid-tumor progression and cancer cell survival. As a non-ABC anti-apoptotic transporter, it supports glutathione (GSH) conjugate transport involved in endocytosis and drug transport. RLIP suppression in ovarian cancer cell lines triggers apoptosis without chemotherapy, and combining RLIP depletion with carboplatin markedly increases cell death in vitro and in vivo. RLIP antisense and RLIP antibodies show consistent growth inhibition and cytotoxic synergy with carboplatin in cultures and OVCAR8 xenografts, supporting RLIP as a therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-the-oncoprotein-rlip-as-novel-therapy-for-ovarian-cancer-research-highlights/370726/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-the-oncoprotein-rlip-as-novel-therapy-for-ovarian-cancer-research-highlights/370726.png","ImageObject",300,407,{"name":42,"@type":43},"Cipher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does RLIP play in ovarian cancer progression?","Question",{"text":63,"@type":64},"RLIP is linked to tumorigenesis and cancer cell survival, and its overexpression correlates with the progression of solid tumors. In ovarian cancer models, reducing RLIP promotes apoptosis and sensitizes cells to drug-induced death.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study inhibit RLIP in ovarian cancer models?",{"text":68,"@type":64},"RLIP inhibition was achieved using RLIP antisense and RLIP-targeting antibodies. The study applied these approaches across multiple ovarian cancer cell lines and evaluated effects in xenograft models.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the effect of combining RLIP inhibition with carboplatin?",{"text":72,"@type":64},"Combining RLIP depletion with carboplatin significantly enhanced cell death in both in vitro and in vivo models. The work also reported cytotoxic synergy between RLIP antisense, RLIP antibodies, and carboplatin in cell cultures and OVCAR8 xenografts.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370726,1790514106,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Krishna et al. Journal of Ovarian Research (2025) 18:150 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-025-01740-0](https://doi.org/10.1186/s13048-025-01740-0)  \nRESEARCH Open Access  \nTargeting the oncoprotein RLIP as novel therapy for ovarian cancer  \nB. Madhu Krishna 1, Pankaj Garg2, Prakash Kul karni 1, David Horne3, Ravi Salgia 1 and Sharad S. Singhal 1*  \nAbstract  \nRal-interacting/binding protein (RLIP/RalBP1) is a multifunctional protein found in the plasma membrane, cytosol, and nucleus, with broad expression across various tissues, including the ovary. In tumorigenesis, RLIP is closely linked to the progression of solid tumors. As a non-ABC anti-apoptotic transporter, it facilitates glutathione (GSH) conjugate transport, which plays a role in receptor-ligand endocytosis and contributes to drug transport and resistance. Its overexpression in multiple malignant cell lines suggests a critical role in cancer cell survival. In ovarian cancer (OC) cell lines, reducing or suppressing RLIP levels whether through antibodies or antisense approaches induces apoptosis, even in the absence of chemotherapy. When combined with carboplatin, RLIP depletion significantly enhances cell death in both in vitro and in vivo models, suggesting that RLIP downregulation promotes apoptosis through both drug-dependent and independent mechanisms. To evaluate the impact of RLIPspecific depletion on apoptosis, we applied RLIP antisense across different OC cell lines and consistently observed growth inhibition and cell death. Further, the cytotoxic synergy between RLIP antisense, RLIP antibodies, and carboplatin was confirmed in cell cultures and OVCAR8 OC cell xenografts. Notably, RLIP inhibition via antibodies was as effective as antisense in enhancing carboplatin’s efficacy in OC xenografts. These findings underscore RLIP asa promising therapeutic target for OC treatment.  \nHighlights  \n• Research indicates that RLIP functions as a leading therapeutic target because it shows potential for fighting human OC at different stages of development.  \n• The reduction of RLIP levels creates notable blocking effects on cell growth and death-inducing effects in OC cells.  \nKeywords RLIP, Antisense, Glutathione-conjugates, Mercapturic acid pathway, Chemotherapeutics, Tumor xenografts  \n*Correspondence:  \nSharad S. Singhal  \n[ssinghal@coh.org](ssinghal@coh.org)  \n1Department of Medical Oncology and Therapeutic Research, Beckman Research Institute of City of Hope, 1500 E Duarte Road, Duarte, CA 91010, USA  \n2Department of Chemistry, GLA University, NH-19, Mathura-Delhi Road, Mathura, Uttar Pradesh 281406, India  \n3Department of Molecular Medicine, Beckman Research Institute of City of Hope, 1500 E Duarte Road, Duarte, CA 91010, USA  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nKrishna et al. Journal of Ovarian Research (2025) 18:150  \nIntroduction  \nGynecologic malignancies account for approximately 11% of new cancer diagnos","cbCaigkPXakkzASC","https://ap.wps.com/l/cbCaigkPXakkzASC","pdf",4498395,14,"English","# Abstract\n# Highlights\n# Introduction\n## Ovarian cancer burden and need for new therapies\n## RLIP biology and rationale for targeting\n## Preclinical evidence and study approach","[{\"question\":\"What role does RLIP play in ovarian cancer progression?\",\"answer\":\"RLIP is linked to tumorigenesis and cancer cell survival, and its overexpression correlates with the progression of solid tumors. In ovarian cancer models, reducing RLIP promotes apoptosis and sensitizes cells to drug-induced death.\"},{\"question\":\"How did the study inhibit RLIP in ovarian cancer models?\",\"answer\":\"RLIP inhibition was achieved using RLIP antisense and RLIP-targeting antibodies. The study applied these approaches across multiple ovarian cancer cell lines and evaluated effects in xenograft models.\"},{\"question\":\"What was the effect of combining RLIP inhibition with carboplatin?\",\"answer\":\"Combining RLIP depletion with carboplatin significantly enhanced cell death in both in vitro and in vivo models. The work also reported cytotoxic synergy between RLIP antisense, RLIP antibodies, and carboplatin in cell cultures and OVCAR8 xenografts.\"}]","Targeting the oncoprotein RLIP as novel therapy for ovarian cancer - Research highlights | PDF",1790190079,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f235face5f5c01325872f54c0ac0ca0.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/389433ac1440772d3ea85337a19927e0.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50c157d4a0d656ae09710eb26f572362.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad379d868cfe1a5efd51e6636671cfa0.webp",980,1306]